Median Technologies SA (EPA:ALMDT)

France · Delayed Price · Currency is EUR

4.850

-0.035 (-0.72%)

Jun 23, 2026, 5:35 PM CET

246.43% (1Y)

Market Cap	185.10M +380.4%
Revenue (ttm)	23.47M +2.2%
Net Income	-34.07M
EPS	-0.93
Shares Out	38.16M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	184,831
Open	4.830
Previous Close	4.885
Day's Range	4.710 - 4.870
52-Week Range	1.272 - 7.270
Beta	0.54
Analysts	Strong Buy
Price Target	11.97 (+146.8%)
Earnings Date	Sep 16, 2026

About Median Technologies

Median Technologies SA engages in providing medical imaging products and services for diagnosing and monitoring cancer patients in both routine clinical practice and clinical drug development with operations spanning in France, the United States, Canada, the United Kingdom, China, and internationally. The company offers iSee for imaging services in clinical trials; eyonis for non-invasive diagnostic tests based on imaging for the diagnosis and treatment of patients suffering from cancer; and iCRO, a central imaging service and AI-powered Imagin... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2002

Employees 199

Stock Exchange Euronext Paris

Ticker Symbol ALMDT

Full Company Profile

Financial Performance

In 2025, Median Technologies's revenue was 23.47 million, an increase of 2.22% compared to the previous year's 22.96 million. Losses were -34.07 million, 35.0% more than in 2024.

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for ALMDT stock is "Strong Buy." The 12-month stock price target is €11.97, which is an increase of 146.80% from the latest price.

Price Target

€11.97

(146.80% upside)

Analyst Consensus: Strong Buy

Stock Forecasts